Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021
The divergent net pricing trends between oral and MAb DMTs may reflect increasing brand and generic competition among oral DMTs and a lack of biosimilar options among MAb DMTs.
Authors
- Nico Gabriel (ORCID: https://orcid.org/0000-0003-1793-2245)
- Inmaculada Hernández (ORCID: https://orcid.org/0000-0002-9692-4982)
- Daniel M. Hartung (ORCID: https://orcid.org/0000-0002-0685-773X)
- Noah Maxwell Feder
- Teresa Cameron
- Walid F. Gellad
Institutions
- Oregon State University (US)
- Oregon State Hospital (US)
- Pharmaceutical Formulations (United States) (US)
- University of Montana (US)
Publication Details
- Journal
- Neurology Clinical Practice
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1212/cpj.0000000000200597
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00